Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).

Cdc25 protein phosphatases are regulators of cyclin-dependent kinases and are often highly expressed in human malignancies. Few small molecule inhibitors of the Cdc25 phosphatase family have been identified and little is known about their disposition, metabolism or efficacy in xenograft models. In this study, the efficacy, pharmacokinetics, and metabolism of a potent quinolinedione Cdc25 phosphatase inhibitor, DA3003-1, in mice was examined. DA3003-1 inhibited the growth of subcutaneous human colon HT29 xenografts in SCID mice. After a single i.v. dose of 5 mg/kg, DA3003-1 was not detectable in plasma or tissues beyond 5 min. In vitro studies showed that DA3003-1 was rapidly dechlorinated and conjugated to glutathione. Following DA3003-1 treatment of tumor-bearing SCID mice, reduced glutathione concentrations in HT29 tumor were decreased to a greater extent and remained decreased for longer than the reduced glutathione concentrations in liver and kidneys. These studies suggest that the minimal antitumor activity of DA3003-1 in mice may be due to its rapid metabolism.

[1]  B. Day,et al.  Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. , 2006, Chemical research in toxicology.

[2]  Chuan-ming Xie,et al.  Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. , 2006, Bioorganic & medicinal chemistry letters.

[3]  P. Hatcher,et al.  Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  B. Ganem,et al.  Selective inhibition of MCF-7(piGST) breast tumors using glutathione transferase-derived 2-methylene-cycloalkenones. , 2005, Journal of medicinal chemistry.

[5]  Y. Sugimoto,et al.  A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity , 2005, Cancer science.

[6]  Bernard Ducommun,et al.  Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases , 2005, Molecular Cancer Therapeutics.

[7]  P. Wipf,et al.  Redox regulation of Cdc25B by novel cell active quinolinediones , 2005 .

[8]  P. Wipf,et al.  Synthesis and Biological Evaluation of Caulibugulones A—E. , 2004 .

[9]  Ivet Bahar,et al.  Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase , 2004, Molecular Pharmacology.

[10]  V. Baldin,et al.  A novel synthetic inhibitor of CDC25 phosphatases: BN82002. , 2004, Cancer research.

[11]  G. Guella,et al.  Kinetic studies of glutathione S-transferase-catalysed processes through on-line liquid chromatography–electrospray mass spectrometry , 2004 .

[12]  P. Wipf,et al.  NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[13]  J. Lazo,et al.  Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione* , 2002, The Journal of Biological Chemistry.

[14]  P. Wipf,et al.  Dual-specificity phosphatases as targets for antineoplastic agents , 2002, Nature Reviews Drug Discovery.

[15]  A. Miyauchi,et al.  Expression of cdc25A and cdc25B proteins in thyroid neoplasms , 2002, British Journal of Cancer.

[16]  Peter Wipf,et al.  Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. , 2002, Molecular pharmacology.

[17]  P. Wipf,et al.  Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A. , 2002, Journal of medicinal chemistry.

[18]  S. Kitamura,et al.  Reductive metabolism of p,p'-DDT and o,p'-DDT by rat liver cytochrome P450. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[19]  P. Wipf,et al.  Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. , 2001, Journal of medicinal chemistry.

[20]  M Monden,et al.  Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. , 2000, Cancer research.

[21]  J. Bolton,et al.  Role of quinones in toxicology. , 2000, Chemical research in toxicology.

[22]  L. Mao,et al.  Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. , 1998, Cancer research.

[23]  V. Jevtovic-Todorovic,et al.  Direct measurement of melphalan conjugation with glutathione: studies with human melanoma cells and mammalian liver. , 1992, The Journal of pharmacology and experimental therapeutics.

[24]  P. Wipf,et al.  NAD ( P ) H : Quinone Oxidoreductase-1-Dependent and-Independent Cytotoxicity of Potent Quinone Cdc 25 Phosphatase Inhibitors , 2004 .

[25]  Robin Johnson,et al.  The role of NAD(P)H: quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells , 2004, Cancer Chemotherapy and Pharmacology.

[26]  Bernard Ducommun,et al.  Inhibitors of the CDC25 phosphatases. , 2003, Progress in cell cycle research.

[27]  M. Monden,et al.  Overexpression of CDC 25 B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma 1 , 2000 .

[28]  G. Powis,et al.  Metabolism and reactions of quinoid anticancer agents. , 1987, Pharmacology & therapeutics.